Sensory polyneuropathy in human immunodeficiency virus-infected patients receiving tuberculosis treatment

C. M. Centner, H. Carrara, T. B. Harrison, Michael G Benatar, Jeannine M. Heckmann

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

SETTING: Human immunodeficiency virus (HIV) infection and treatments for HIV infection and tuberculosis (TB) are associated with the risk of developing sensory polyneuropathy (SPN). Vitamin B6 and genetically determined slow isoniazid (INH) acetylation are believed to play key roles in the development of SPN in a TB treatment setting. OBJECTIVE: To investigate slow acetylation and risk factors for SPN in HIV-infected patients receiving TB treatment, and establish vitamin B6 status and its association with SPN. METHODS: HIV-infected in-patients were prospectively assessed after initiating TB treatment and vitamin B6 supplementation, and monthly during hospitalisation. SPN was defined as ≥1 symptom plus ≥1 sign. NAT2 genotyping predicted acetylation status, and plasma high performance liquid chromatography estimated vitamin B6 status. A survival analysis estimated hazard ratios (HRs) for SPN during TB treatment. RESULTS: Of 116 participants, 56% had SPN at study entry. Participants developed SPN at a rate of 26/ 100 person-months (95%CI 18-35) during TB treatment, which was independently associated with slow acetylation (HR 2.5; 95%CI 1.1-5.9), as well as black race, previous TB and extra-pulmonary/disseminated TB. Vitamin B6 status was normal, irrespective of SPN. CONCLUSIONS: Risk factors for SPN suggest a multifactorial pathogenesis related to INH and other potential nervous system insults. SPN developed despite normal vitamin B6 status, suggesting other mechanisms of injury.

Original languageEnglish
Pages (from-to)27-33
Number of pages7
JournalInternational Journal of Tuberculosis and Lung Disease
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Polyneuropathies
Tuberculosis
HIV
Vitamin B 6
Acetylation
Therapeutics
Virus Diseases
Isoniazid
Survival Analysis
Pulmonary Tuberculosis
Nervous System
Hospitalization
High Pressure Liquid Chromatography

Keywords

  • Acetylation
  • Isoniazid
  • Neuropathy
  • Pyridoxine
  • Vitamin B6

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Sensory polyneuropathy in human immunodeficiency virus-infected patients receiving tuberculosis treatment. / Centner, C. M.; Carrara, H.; Harrison, T. B.; Benatar, Michael G; Heckmann, Jeannine M.

In: International Journal of Tuberculosis and Lung Disease, Vol. 18, No. 1, 01.01.2014, p. 27-33.

Research output: Contribution to journalArticle

@article{d5820d5ebeb54c2abfd02247868afba5,
title = "Sensory polyneuropathy in human immunodeficiency virus-infected patients receiving tuberculosis treatment",
abstract = "SETTING: Human immunodeficiency virus (HIV) infection and treatments for HIV infection and tuberculosis (TB) are associated with the risk of developing sensory polyneuropathy (SPN). Vitamin B6 and genetically determined slow isoniazid (INH) acetylation are believed to play key roles in the development of SPN in a TB treatment setting. OBJECTIVE: To investigate slow acetylation and risk factors for SPN in HIV-infected patients receiving TB treatment, and establish vitamin B6 status and its association with SPN. METHODS: HIV-infected in-patients were prospectively assessed after initiating TB treatment and vitamin B6 supplementation, and monthly during hospitalisation. SPN was defined as ≥1 symptom plus ≥1 sign. NAT2 genotyping predicted acetylation status, and plasma high performance liquid chromatography estimated vitamin B6 status. A survival analysis estimated hazard ratios (HRs) for SPN during TB treatment. RESULTS: Of 116 participants, 56{\%} had SPN at study entry. Participants developed SPN at a rate of 26/ 100 person-months (95{\%}CI 18-35) during TB treatment, which was independently associated with slow acetylation (HR 2.5; 95{\%}CI 1.1-5.9), as well as black race, previous TB and extra-pulmonary/disseminated TB. Vitamin B6 status was normal, irrespective of SPN. CONCLUSIONS: Risk factors for SPN suggest a multifactorial pathogenesis related to INH and other potential nervous system insults. SPN developed despite normal vitamin B6 status, suggesting other mechanisms of injury.",
keywords = "Acetylation, Isoniazid, Neuropathy, Pyridoxine, Vitamin B6",
author = "Centner, {C. M.} and H. Carrara and Harrison, {T. B.} and Benatar, {Michael G} and Heckmann, {Jeannine M.}",
year = "2014",
month = "1",
day = "1",
doi = "10.5588/ijtld.13.0375",
language = "English",
volume = "18",
pages = "27--33",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "1",

}

TY - JOUR

T1 - Sensory polyneuropathy in human immunodeficiency virus-infected patients receiving tuberculosis treatment

AU - Centner, C. M.

AU - Carrara, H.

AU - Harrison, T. B.

AU - Benatar, Michael G

AU - Heckmann, Jeannine M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - SETTING: Human immunodeficiency virus (HIV) infection and treatments for HIV infection and tuberculosis (TB) are associated with the risk of developing sensory polyneuropathy (SPN). Vitamin B6 and genetically determined slow isoniazid (INH) acetylation are believed to play key roles in the development of SPN in a TB treatment setting. OBJECTIVE: To investigate slow acetylation and risk factors for SPN in HIV-infected patients receiving TB treatment, and establish vitamin B6 status and its association with SPN. METHODS: HIV-infected in-patients were prospectively assessed after initiating TB treatment and vitamin B6 supplementation, and monthly during hospitalisation. SPN was defined as ≥1 symptom plus ≥1 sign. NAT2 genotyping predicted acetylation status, and plasma high performance liquid chromatography estimated vitamin B6 status. A survival analysis estimated hazard ratios (HRs) for SPN during TB treatment. RESULTS: Of 116 participants, 56% had SPN at study entry. Participants developed SPN at a rate of 26/ 100 person-months (95%CI 18-35) during TB treatment, which was independently associated with slow acetylation (HR 2.5; 95%CI 1.1-5.9), as well as black race, previous TB and extra-pulmonary/disseminated TB. Vitamin B6 status was normal, irrespective of SPN. CONCLUSIONS: Risk factors for SPN suggest a multifactorial pathogenesis related to INH and other potential nervous system insults. SPN developed despite normal vitamin B6 status, suggesting other mechanisms of injury.

AB - SETTING: Human immunodeficiency virus (HIV) infection and treatments for HIV infection and tuberculosis (TB) are associated with the risk of developing sensory polyneuropathy (SPN). Vitamin B6 and genetically determined slow isoniazid (INH) acetylation are believed to play key roles in the development of SPN in a TB treatment setting. OBJECTIVE: To investigate slow acetylation and risk factors for SPN in HIV-infected patients receiving TB treatment, and establish vitamin B6 status and its association with SPN. METHODS: HIV-infected in-patients were prospectively assessed after initiating TB treatment and vitamin B6 supplementation, and monthly during hospitalisation. SPN was defined as ≥1 symptom plus ≥1 sign. NAT2 genotyping predicted acetylation status, and plasma high performance liquid chromatography estimated vitamin B6 status. A survival analysis estimated hazard ratios (HRs) for SPN during TB treatment. RESULTS: Of 116 participants, 56% had SPN at study entry. Participants developed SPN at a rate of 26/ 100 person-months (95%CI 18-35) during TB treatment, which was independently associated with slow acetylation (HR 2.5; 95%CI 1.1-5.9), as well as black race, previous TB and extra-pulmonary/disseminated TB. Vitamin B6 status was normal, irrespective of SPN. CONCLUSIONS: Risk factors for SPN suggest a multifactorial pathogenesis related to INH and other potential nervous system insults. SPN developed despite normal vitamin B6 status, suggesting other mechanisms of injury.

KW - Acetylation

KW - Isoniazid

KW - Neuropathy

KW - Pyridoxine

KW - Vitamin B6

UR - http://www.scopus.com/inward/record.url?scp=84892612159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892612159&partnerID=8YFLogxK

U2 - 10.5588/ijtld.13.0375

DO - 10.5588/ijtld.13.0375

M3 - Article

VL - 18

SP - 27

EP - 33

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 1

ER -